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The premetastatic niche is a predetermined site of
metastases, awaiting the influx of tumor cells. How-
ever, the regulation of the angiogenic switch at these
sites has not been examined. Here, we demonstrate
that the calcineurin and nuclear factor of activated
T cells (NFAT) pathway is activated specifically in
lung endothelium prior to the detection of tumor cells
that preferentially metastasize to the lung. Upregula-
tion of the calcineurin pathway via deletion of its
endogenous inhibitor Dscr1 leads to a significant
increase in lung metastases due to increased ex-
pression of a newly identified NFAT target, Angio-
poietin-2 (ANG2). Increased VEGF levels specifically
in the lung, and not other organ microenvironments,
trigger a threshold of calcineurin-NFAT signaling that
transactivates Ang2 in lung endothelium. Further,
we demonstrate that overexpression of DSCR1 or
the ANG2 receptor, soluble TIE2, prevents the acti-
vation of lung endothelium, inhibiting lung meta-
stases in our mouse models. Our studies provide
insights into mechanisms underlying angiogenesis
in the premetastatic niche and offer targets for lung
metastases.INTRODUCTION
Metastasis is a multistep process that requires tumor cells to
acquire properties that allow them to escape from the primary
tumor site, travel to a distant site, seed, and form tumors. Previ-
ous studies have described the formation of a ‘‘premetastatic
niche’’ prior to the arrival of tumor cells marked by VEGFR1+bone-marrow-derived endothelial progenitor cells or CD11b+
myeloid cells, depending on the tumor model utilized (Erler
et al., 2009; Kaplan et al., 2005). The development of the preme-
tastatic niche is regulated in part by soluble factors produced by
the primary tumor to communicate with cells at the future site of
metastasis. The formation of micro- and macro-metastases at
later stages of disease are thought to involve tumor cell recruit-
ment of endothelial progenitor cells (De Palma et al., 2003) as
well as TIE2+ monocytes (De Palma et al., 2005; Welford et al.,
2011) to create a proangiogenic environment with high levels
of vascular endothelial growth factor (VEGF) and other proangio-
genic factors, which trigger the angiogenic switch (Bergers and
Hanahan, 2008; Saharinen et al., 2011). However, little is known
about the role of local endothelial cell activation at the premeta-
static niche or during the early stages of micrometastases
formation.
We and others have previously demonstrated that a key intra-
cellular mediator of VEGF signaling in endothelial cells is the
calcineurin and nuclear factor of activated T cells (NFAT) path-
way (Hesser et al., 2004; Minami et al., 2004). VEGF activation
of VEGFR2 on endothelial cells leads to increased intracellular
calcium and activation of the calcium regulated Ser/Thr phos-
phatase calcineurin. Calcineurin dephosphorylates the NFAT
family of transcription factors permitting their nuclear entry and
transactivation of proangiogenic genes followed by induction
of its endogenous inhibitor, the Down syndrome candidate
region 1 (Dscr1) gene (Minami et al., 2004, 2006). Upregulation
of DSCR1 creates a negative feedback loop in which DSCR1
inhibits calcineurin activity by direct interaction, thus attenuating
NFAT nuclear import and transactivation of its targets. To main-
tain vascular homeostasis under physiologic conditions, this
feedback loop works to minimize endothelial cell activation in
the presence of VEGF. However, during tumor progression
with pathologically high levels of VEGF produced as a conse-
quence of increasing tumor mass, calcineurin-NFAT is con-
stitutively active as endogenous DSCR1 levels are no longerCell Reports 4, 709–723, August 29, 2013 ª2013 The Authors 709
Figure 1. Calcineurin-NFAT Signaling Is Activated in Metastatic Lung Vasculature Endothelium
(A) Representative images of lung sections harvested fromDscr1-lacZ-hprtmice 5 days after inoculation with B16-F10 (i.v.) and immunostained with LacZ (blue or
green), anti-PECAM1 (red), and DAPI. n = 6; the scale bar represents 50 mm.
(B) qPCR analysis of melanoma-specific tyrosinase, lacZ regulated by the Dscr1 promoter, and endogenous Dscr1 mRNA in the lungs of mice after B16-F10
tail vein injection at the indicated days. Data are presented as mean ± SEM relative to b-actin mRNA in triplicate; n = 5. *p < 0.05 compared to day 0 in each
target gene.
(C) Representative images of lungs from Dscr1-lacZ-hprt mice 7 days after LLC inoculation in the flank and immunostained with LacZ (blue or green), anti-
PECAM1 (red), and DAPI. n = 6; the scale bar represents 50 mm.
(D) Representative images of lungs harvested from Dscr1-lacZ-hprtmice with B16-F10 tumors or LLC flank tumors and treated daily with cyclosporin A (CsA) i.p.
for 5 or 7 days, respectively. Lungs were sectioned and stained for LacZ. n = 6; scale bar, 50 mm.
(legend continued on next page)
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sufficient to inhibit calcineurin activity. Deregulation of this
pathway by either loss of Dscr1 or trisomic expression of
Dscr1 inhibits endothelial cell activation and ultimately tumor
angiogenesis during primary tumor growth by two different
mechanisms (Baek et al., 2009; Ryeom et al., 2008). The role
of calcineurin pathway activation in the vasculature of metastatic
lesions has not yet been examined.
In the present study, we examined endothelial cell activation in
early metastatic lesions and show that the calcineurin-NFAT-
DSCR1 signaling axis is activated in the vasculature at these
sites. Attenuation of this pathway by genetic manipulation of
DSCR1 overexpression in transgenic mouse models shows inhi-
bition of lung metastases, whereas Dscr1 deletion and constitu-
tively activated calcineurin accelerates the formation of lung
metastases. In the metastatic lung microenvironment, we identi-
fied high levels of VEGF specifically in the lungs leading to acti-
vation of lung endothelium as indicated by high levels of VEGF
receptor 2 (VEGFR2) phosphorylation and calcineurin-NFAT-
mediated Angiopoietin-2 (ANG2) induction. Immunohistochem-
ical analyses of lung metastases resected from patients with
primary colorectal tumors confirmed activation of NFAT and
increased expression of ANG2 specifically in the endothelium
of lungmetastases and not in primary colorectal tumors. Further,
adenoviral-mediated delivery of soluble TIE2 to sequester ANG2
was sufficient to reverse of the formation of lung metastases in
Dscr1-null mice. Collectively, our data provide insights into
endothelial cell activation in early metastatic lesions in the lungs
and point to DSCR1 and soluble TIE2 (sTIE2) as potential thera-
peutic targets in lung metastases.
RESULTS
Calcineurin Signaling Is Activated in the Vasculature of
the Premetastatic Niche in the Lung
To examine whether calcineurin was activated in early metasta-
tic lesions, we utilized Dscr1-LacZ mice in which LacZ was
targeted into the hprt locus and controlled byDscr1’s native pro-
moter, allowing LacZ upregulation to serve as a surrogate for
calcineurin-NFAT activity. Using a lung colonization assay in
these mice, we found significant LacZ expression in the lung
5 days after tail vein injection of B16-F10 melanoma cells
(Figures 1A and S1A) but no expression in the liver or kidney (Fig-
ure S1B). Coimmunofluorescence of lung sections with anti-
LacZ and anti-PECAM1 confirmed increased DSCR1 expression
specifically in the lung endothelium as early as 5 days after
melanoma cell injection (Figure 1A). To assess the arrival of
tumor cells in the lungs, we quantified tyrosinase messenger
RNA (mRNA) as a marker of melanoma cells (Figure 1B). LacZ
mRNA as an indication of DSCR1 transcription was significantly
upregulated 1 day after tumor cell injection, while tyrosinase
mRNA expression only increased 7 days after B16-F10 inocula-(E) Representative images of sections from lungmetastases (upper row) or primary
NFATc2. Serial sections from lung metastases were immunostained with the end
indicates nuclear localized NFATc2 in endothelium. Sections from n = 20 patient
(F) Representative images of sections from lung metastases or adjacent normal
scale bar represents 50 mm. Arrow indicates DSCR1 expression. Sections from
See also Figure S1 and Tables S1, S3, and S4.tion. Endogenous Dscr1 mRNA expression increased 3–5 days
after tumor cell injection validating calcineurin-NFAT activation
in the lung prior to detection of tumor cells (Figure 1B). To confirm
these data, we utilized two other metastatic tumor models.
Lewis lung carcinoma (LLC) cells injected into the flank will spon-
taneously metastasize to the lung and renal cell carcinoma
(Renca) cells injected under the kidney capsule also metastasize
to the lung. Upregulation of LacZ specifically in the lung endothe-
lium after tumor cell inoculation was also observed in these
models (Figures 1C, S1C, and S1D), with LacZ expression abro-
gated upon treatment with the calcineurin-specific inhibitor
cyclosporin A (CsA) in both the B16-F10 and LLC tumor models
(Figure 1D).
To determine whether calcineurin activation was observed in
patients with metastatic disease, we examined NFAT subcellular
localization by immunohistochemistry in metastatic lung lesions
and found significant nuclear localization of NFATc2 in tumor
endothelial cells that were labeled by CD34 staining of serial
sections (Figure 1E). In contrast, NFATc2 was localized to the
cytosol in endothelium and alveolar epithelium of adjacent
normal lung sections (Figure S1E). DSCR1 expression was also
upregulated in metastatic tumor endothelium (Figure 1F) as
compared to normal lung endothelium. Examination of metasta-
tic lesions from 20 different patients confirmed these observa-
tions (Table S1), and sections from each patient were quantified
for NFAT nuclear localization (Figure S1F). Collectively, these
findings imply calcineurin-NFAT activation specifically in the
vasculature of metastatic lung lesions.
Loss of DSCR1 and Upregulated Calcineurin-NFAT
Signaling Leads to Increased Lung Metastases
The relationship between primary tumor size and the extent of
metastatic disease is not well understood. We have previously
shown that primary tumor growth is significantly inhibited in
Dscr1 null mice due to suppression of tumor angiogenesis
(Ryeom et al., 2008). Here, we examined the incidence of lung
colonization in Dscr1/ mice after B16-F10 injection. Ten days
after intravenous (i.v.) tumor cell inoculation, there was a signifi-
cant increase in gross lung lesions and decreased survival of
Dscr1/ mice versus wild-type (WT) controls (Figures 2A and
2B). Next, we utilized 3LLC tumor cells that spontaneously
metastasize to the lung after subcutaneous flank injection. As ex-
pected, primary 3LLC tumor growth was significantly smaller in
Dscr1/ mice. However, macroscopic metastatic lesions were
clearly visible in the lungs of Dscr1/ mice as compared to
WT controls (Figure 2C). Similarly, orthotopic injection of Renca
cells into the kidney capsule and LLC footpad injection also
confirmed a dramatic increase in lung metastases in mice lack-
ing Dscr1 (Figures 2D, 2E, S2A, and S2B). Collectively, our
data using multiple tumor cell lines and models of metastases
illustrate that metastases to the lung does not correlate withcolon tumors (lower row) resected from patients and immunostainedwith anti-
othelial marker anti-CD34 on the right. The scale bar represents 50 mm. Arrow
s were examined.
lung tissue resected from patients and immunostained with anti-DSCR1. The
n = 20 patients were examined.
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Figure 2. Deregulation of Calcineurin-NFAT Signaling by Loss of its Endogenous Inhibitor, Dscr1, Leads to Increased Metastases Even with
Decreased Primary Tumor Growth
(A) Representative images of lungs harvested 10 days after WT or Dscr1/ mice were injected with B16-F10 (i.v.) cells. n = 10. Quantification of the number of
tumor colonies per high-powered field (hpf) is on the right.
(B) Kaplan-Meyer survival curves of B16-F10-bearing WT or Dscr1/ mice (n = 12). *p < 0.01 compared to WT in each day.
(legend continued on next page)
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primary tumor size and that upregulation of calcineurin signaling
due to loss of Dscr1 promotes metastatic progression.
Our prior studies demonstrated that calcineurin hyperactiva-
tion in the vasculature during primary tumor growth suppressed
angiogenesis by promoting endothelial cell apoptosis due to pre-
cocious NFAT-dependent transactivation of Fas ligand (Ryeom
et al., 2008). Thus, we examined endothelial cell apoptosis in
the lungs of Dscr1/mice after B16-F10 inoculation by staining
for TUNEL+PECAM+ cells. In comparison to mice injected with
the bacterial toxin lipopolysaccharide (LPS), which triggers
widespread endothelial cell death in the lungs (Minami et al.,
2009), Dscr1/ mice injected with tumor cells showed no
TUNEL-positive lung endothelial cells (Figure S2C). To investi-
gate the mechanism by which calcineurin hyperactivation pro-
motes lung metastases, we performed a complementary DNA
(cDNA) microarray on primary lung endothelial cells isolated
from WT and Dscr1/ mice treated with VEGF to identify differ-
entially expressed genes. A heatmap generated from this data
did not show Fas ligand upregulation, but it did identify a number
of genes that were highly expressed in Dscr1/ lung endothelial
cells (Figure 3A). While the expected NFAT-dependent inflam-
matory and proangiogenic genes were upregulated, we found
that Ang2 levels were also significantly increased in primary
Dscr1/ mouse lung endothelial cells (Figure 3A) and in human
lung endothelial cells after Dscr1 knockdown (Figure 3B). Quan-
titative PCR (qPCR) analyses demonstrated decreased Dscr1
mRNA in human lung endothelium after DSCR1 knockdown
using si-Dscr1 constructs and confirmed increased Ang2
mRNA expression in these cells (Figure 3C). Microarray analysis
of human endothelial cells infected with either adenoviral Dscr1
or a control vector further confirmed the calcineurin-NFAT
dependence of Ang2 as it was found to be the most downregu-
lated gene in the presence of DSCR1 overexpression after VEGF
treatment (Figure S3A). Moreover, significantly decreased Ang2
mRNA expression in VEGF-treated lung endothelial cells with
DSCR1 overexpression was detected by qPCR, confirming its
regulation by calcineurin-NFAT signaling (Figure S3B).
ANG2 is related to ANG1, a family of endothelial-specific cyto-
kines whose receptors are the TIE1 and TIE2 receptor tyrosine
kinases. ANG2 expression is tightly regulated both at the tran-
scriptional and posttranscriptional levels and is produced pre-
dominantly by activated endothelium counteracting blood vessel
stability mediated by ANG1 (Eklund and Saharinen, 2013).
Although GATA2 and Ets1 have been shown to regulate the
ANG2 promoter (Hegen et al., 2004; Simon et al., 2008), a role
for the NFAT family of transcription factors in ANG2 expression
has not been previously investigated, although multiple NFAT
binding sites were identified in introns 1 and 2 of the Ang2(C) Images of tumors or lungs harvested from WT or Dscr1/ mice 20 days after
of lung sections are shown on the bottom. The scale bar represents 50 mm. M
compared toWT; n = 6. Themetastases invasion rate (graph on right) was quantifi
to WT; n = 6.
(D) Representative images of tumors or lungs harvested fromWT orDscr1/mice
Representative H&E staining of lung sections are shown on the bottom. The scale
(E) Representative images of tumors or lungs harvested from WT or Dscr1/ mi
from lung tissue sections are shown on the bottom. The scale bar represents 50
pendent experiments.
See also Figure S2.enhancer region (Figure 3D). An NFATc1 chromatin immunopre-
cipitation (ChIP) of human lung endothelial cells showed that
NFATc1 specifically binds introns 1 and 2 in the Ang2 enhancer
region after VEGF treatment (Figures 3E and S4A), with expres-
sion of NFATc1 also activating anAng2 reporter containing either
intron 1 or intron 2 or both (Figure 3F). VEGF treatment of lung
endothelial cells transfected with the Ang2 reporter demon-
strated activation of reporter constructs when intron 1 or 2
were present which were inhibited by CsA (Figure S4B), confirm-
ing the calcineurin-NFAT-dependent regulation of Ang2 expres-
sion in endothelial cells after VEGF treatment.
VEGF and ANG2 Expression in the Vasculature of Lung
Metastases
While Ang2 mRNA levels in the lungs of B16-F10 tumor-bearing
WT and Dscr1/ mice were initially similar, its expression was
dramatically upregulated in Dscr1/ lungs beginning 6 days
after tumor cell injection (Figure 4A). Presumably, the lack of cal-
cineurin inhibition by DSCR1 prevents Ang2 expression in the
lungs fromplateauing, as observed inWTmice, but instead leads
to increased calcineurin-NFAT activity and notably higher levels
of Ang2 message. Immunofluorescence analysis indicates
endothelial expression of ANG2 by colocalization with PECAM1
(Figure 4B). ANG2 levels were significantly increased in the
plasma of tumor-bearingmice andwere also upregulated specif-
ically in the lung, but not in the heart (Figure 4C). The lack of
increased ANG2 levels in primary tumors further suggests an
ANG2 specific role in early metastatic lesions (Figure 4D). To
determine whether ANG2 expression in lung metastases is
reflected in patients, we screened for ANG2 expression in lung
metastases, primary lung adenocarcinoma, and squamous
cell carcinomas by immunohistochemistry. Significant ANG2
expression was detected in metastatic lung endothelium as
compared to the vasculature of primary lung tumors or in normal
lung endothelium (Figures 4E and S5).
Upregulated ANG2 levels antagonize ANG1-TIE2 interactions,
causing vessel regression that leads to hypoxia and a subse-
quent increase in VEGF production (Holash et al., 1999). Thus,
increased ANG2 expression in the lungs of Dscr1/ mice after
tumor cell inoculation would predict that VEGF levels would be
higher in the lungs. To test the interplay of ANG2 and VEGF in
early metastatic lesions in the lung, we examined both VEGF
levels and VEGFR2 activation during tumor growth. VEGF was
appreciably upregulated in LLC tumor-bearing Dscr1/ mice
both in the plasma and the lungs, but not in the kidney or liver,
demonstrating the specificity of increased lung VEGF (Figure 5A).
However, as expected, a comparison of VEGF expression in the
lungs versus flank tumors demonstrated higher VEGF levels insubcutaneous (s.c.) inoculation with 3LLC cells. Representative H&E staining
iddle bar graph: primary tumor volumes are shown (graph on left); *p < 0.05
ed as the ratio of metastatic area versus normal lung area. *p < 0.001 compared
30 days after orthotopic implantation of Renca cells under the kidney capsule.
bar represents 50 mm. Data are representative of six independent experiments.
ce 14 days after footpad implantation of LLC cells. Representative H&E stains
mm. Arrows indicate metastatic lesions. Data are representative of ten inde-
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(legend on next page)
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tumor xenografts (Figure 5B) due to high VEGF production by
both LLC and B16-F10 tumor cells. Next, VEGFR2 activation
was assessed by phospho-VEGFR2 immunofluorescence in pri-
mary tumors and lungs of WT and Dscr1/ mice. While there
was no detectable difference in VEGFR2 activation in primary
tumors, there was significant phospho-VEGFR2 immunostaining
in the lungs ofDscr1/mice, but not in WTmice (Figure 5C). We
further examined VEGFR2 activation in the lung, liver, and kidney
after VEGF administration and found the highest level of phos-
pho-VEGFR2 in lung lysates (Figure 5D). This increased VEGFR2
activation in the lung may be a consequence of increased sensi-
tivity to VEGF as compared to other organ sites. These data sug-
gest that preferential metastases to the lung may be due in part
to the increased sensitivity of lung endothelium to VEGF. Further
investigation of VEGF expression in WT and Dscr1/ mice with
B16-F10 flank tumors demonstrated increased VEGF levels in
the lungs of both control and tumor bearing Dscr1/ mice (Fig-
ure 5E) similar to our observations with LLC tumors.
We have previously published that constitutively activated cal-
cineurin signaling as a consequence ofDscr1 loss leads to NFAT
transactivation of the proapoptotic gene FasL on tumor endothe-
lium (Ryeom et al., 2008). The absence of Fas ligand in our lung
endothelium microarrays and the lack of apoptosis in lung
metastases lead us to investigate how calcineurin-NFAT sig-
naling could differentially regulate target genes in endothelial
cells. One difference between the vasculature of lung metasta-
ses versus xenograft tumors is significantly higher VEGF levels
in the primary tumor. Thus, we examined Ang2 and FasL
mRNA levels by qPCR in primary mouse lung endothelial cells
after the addition of a range of VEGF concentrations and found
that Ang2 mRNA was preferentially upregulated at lower VEGF
expression, while FasL mRNA was increased at considerably
higher VEGF levels (Figure 5F). Taken together, these findings
support a model whereby specific calcineurin-NFAT targets
can be transactivated by differential VEGF levels.
Inhibition of Lung Metastases by Overexpression of
DSCR1 or Soluble TIE2
Activation of calcineurin-NFAT signaling and upregulation of
ANG2 expression was observed in the vasculature of micro-
scopic lung metastases. Thus, we investigated whether genetic
inhibition of calcineurin-NFAT by endothelial overexpression of
DSCR1, or sequestering ANG2 with sTIE2, would be sufficientFigure 3. VEGF-Mediated Calcineurin-NFAT Signaling in Early Metasta
(A and B) Heatmap of gene expression for upregulated (red) and downregulated (
fromWT or Dscr1/mice and (B) primary lung endothelial cells treated with smal
to the median (black).
(C) qPCR of Dscr1 and Ang2 expression in lung endothelial cells treated with D
cyclophilin A performed in triplicate; n = 3. *p < 0.0001 and **p < 0.05 compared
(D) ChIP sequencing (ChIP-seq) genome browser view of the Ang2 gene. Histon
purple, respectively. NFATc1 binding sites and intensity are shown in red. VEGF-re
outlined in red.
(E) Graphs indicate the ChIP enrichment level of with anti-NFATc1 or Isotype matc
are represented as the mean ± SD from three independent experiments. *p < 0.0
(F) Human primary lung endothelial cells were transiently transfected with the indic
or vector alone (pcDNA3). Results are represented as the mean ± SD of luciferase
compared to control (pcDNA3 alone).
See also Figure S3 and Tables S2 and S3.to inhibit lung metastases. We generated transgenic mice with
human DSCR1 fused to LacZ driven by the TIE2 promoter for
endothelial specific expression demonstrated by LacZ and
PECAM1 costaining in both primary flank tumors and in the
lung (Figure 6A). Quantification of human DSCR1 mRNA by
qPCR in flank tumors isolated fromTie2-DSCR1-LacZ transgenic
mice and WT littermates shows significant expression of h
DSCR1 in tumors from transgenicmice, but not controlmice (Fig-
ure 6B), further indicating endothelial-specific expression of the
transgene. Inhibition of calcineurin-NFAT signaling was exam-
ined by transfecting a construct with NFAT response elements
driving transcription of a luciferase reporter gene into primary
lung endothelial cells isolated from Tie2-DSCR1-LacZ and litter-
mate controls. After treatment of cells with VEGF,WT endothelial
cells show considerable luciferase activity that was significantly
inhibited in DSCR1 transgenic endothelial cells (Figure 6C).
Next, we confirmed that endothelial-specific DSCR1 overex-
pression was sufficient to block primary tumor growth (Figures
6D–6F) and inhibit tumor angiogenesis as shown by decreased
microvessel density (Figure 6F). To determine whether lung
metastases would be inhibited in our Tie2-DSCR1-LacZ trans-
genic mice, mice were inoculated subcutaneously with B16-
F10 melanoma cells and lungs were examined after 3 weeks.
There was a significant decrease in the incidence of lung metas-
tases in DSCR1 transgenic mice (Figures 6G and 6H), indicating
that endothelial overexpression of DSCR1 is sufficient to inhibit
calcineurin-NFAT signaling and block both primary tumor growth
and lung metastases.
sTIE2 binds to both ANG1 and ANG2 thus we examined the
therapeutic potential of sTIE2 delivery in preventing lung metas-
tases by generating an adenovirus with the TIE2 extracellular
domain fused to an immunoglobulin Fc fragment (Ad-sTIE2-
Fc). Measurement of plasma sTIE2 levels after systemic delivery
found significant levels of sTIE2 in the plasma up to 20 days after
injection (Figure 7A). Moreover, Ad-sTIE2-Fc treatment signifi-
cantly reduced ANG2 in the lungs of WT and Dscr1/ mice
and also reduced ANG1 expression in the lungs of Dscr1/
mice (Figure 7B). To ensure hyperactivation of calcineurin-
NFAT in the metastatic niche, we used Dscr1/mice to investi-
gate the efficacy of Ad-sTIE2-Fc on inhibiting metastases.
Pretreatment ofDscr1/mice with sTIE2 followed by orthotopic
implantation of Renca tumor cells lead to a significant decrease
in lungmetastases (Figure 7C). Upon delivery of sTIE2 1 day afterses in the Lung Upregulates ANG2 Expression in the Vasculature
green) genes after VEGF treatment of (A) primary lung endothelial cells isolated
l interfering RNA against Dscr1 or control (scrambled). Color intensity is relative
scr1 or control siRNA. Results are represented as the mean ± SD relative to
to si-control.
e marks for H3K4me3, H3K27Ac, and H4Ac are shown in green, yellow, and
sponsive NFATc1 binding sites that colocalize with histone enhancermarks are
hed control immunoglobulin G relative to total input by ChIP-qPCR. The results
01 compared to NFATc1 immunoprecipitation without VEGF.
ated ANG2-luciferase (luc) construct, and either a NFATc1 expression plasmid
light units (relative to pcDNA3 control) performed in triplicate; n = 3. *p < 0.01
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Figure 4. Increased ANG2 Expression in Lung Metastases
(A) qPCR of Ang2mRNA in the lungs of tumor-bearing WT or Dscr1/ mice at the indicated days after tumor cell injection. Data are represented as the mean ±
SEM relative to b-actin mRNA; n = 4. *p < 0.05 compared to WT at each time point.
(B) Representative immunofluorescence images of ANG2 (green) and PECAM1 (red) staining of lungs harvested fromWTorDscr1/mice 10 days after tumor cell
inoculation. The scale bar represents 50 mm; n = 4.
(C) ANG2 levels were quantified by ELISA in lung and heart extracts and in the plasma of WT or Dscr1/mice with and without tumors. Data are represented as
mean ± SEM; n = 10. *p < 0.05 compared to controls.
(legend continued on next page)
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tail vein inoculation of B16-F10 melanoma cells, we continued to
observe a significant decrease in lung lesions (Figure 7D). Micro-
array analysis of lungs harvested from Dscr1/ tumor-bearing
mice after sTIE2 treatment revealed significant downregulation
of not only Ang2 but also a number of genes that indicate endo-
thelial activation such as Vcam1 and E-selectin (Figures 7E and
7F). These data suggest that targeting either the calcineurin
pathway or ANG2 is sufficient to suppress activation of the
lung endothelium in early metastatic lesions, offering targets in
the treatment of lung metastases.
DISCUSSION
Metastasis is a multistep process and is responsible for most
cancer deaths. While much investigation has been devoted to
understanding how tumor cells invade and extravasate from
the primary site (Valastyan and Weinberg, 2011), less is under-
stood about regulation of themetastatic site. Indeed, few studies
have investigated angiogenesis regulation in the metastatic
niche. Here, we examined calcineurin-NFAT signaling in lung
endothelium of early metastatic lesions and found that its
activation promotes metastases due to increased expression
of Angiopoietin-2 (ANG2), a newly identified NFAT target. We
identified ANG2 upregulation as a link between increased
VEGF in the lung and increased angiogenesis in the metastatic
niche promoting lung metastases. Finally, we demonstrate that
inhibition of ANG2 expression by DSCR1 overexpression or by
adenoviral delivery of soluble TIE2 (sTIE2) is sufficient to sup-
press activation of the lung endothelium in early metastatic
lesions, offering targets in the treatment of lung metastases.
Our data suggest that increased VEGF in the lung as a conse-
quence of primary tumor growth activates the calcineurin-
NFAT pathway upregulating ANG2 in lung endothelium, promot-
ing angiogenesis and metastatic growth.
VEGF is the best-characterized endothelial cell mitogen with
drugs targeting VEGF or its receptors to block tumor angiogen-
esis currently in clinical use (Wu and Staton, 2012). However,
little is known about the intracellular signaling pathways that
mediate VEGF effects in endothelial cells. We and others have
identified the calcium-responsive calcineurin-NFAT pathway as
a key intracellular regulator of VEGF in endothelial cells. VEGF
ligation to VEGF receptors on endothelial cells leads to increased
intracellular calcium levels and subsequent calcineurin activa-
tion. Its downregulation is modulated in part by its endogenous
inhibitor, the Dscr1 gene (Minami et al., 2004).
DSCR1 is transactivated in a calcineurin-NFAT-dependent
manner and functions in a classic negative feedback loop,
directly blocking calcineurin phosphatase function. Genetic
deletion of Dscr1 in a transgenic mouse model leads to hyperac-
tivation of calcineurin-NFAT signaling (Minami et al., 2009;(D) ANG2 levels were quantified in lung and tumor extracts harvested from tum
(2) 1,200 mm3 to (3) 1,500 mm3. Data are represented as mean ± SEM; n = 3
(E) Representative images of tumor sections from patients. Tissues from either
immunostained with anti-ANG2. Arrow indicates ANG2 expression in endothelial c
endothelium from metastatic lung tumors, primary lung tumors, and normal lun
section from six patients with metastatic lung tumors and 7 patients with primar
See also Figures S4 and S5 and Table S4.Ryeom et al., 2008). Although primary tumor growth was in-
hibited in these mice due to suppression of tumor angiogenesis,
here we show a significant increase in lung metastases. To
investigate the role of calcineurin-NFAT in promoting lung
metastases, we generated a LacZ reporter mouse driven by
the native Dscr1 promoter as an indication of calcineurin-NFAT
signaling. Inoculation of LLC in the flanks of these mice revealed
calcineurin activation in lung, but not other organ endothelium,
prior to the arrival of tumor cells that preferentially metastasize
to the lung. Similarly, tail vein injection of tumor cells led to acti-
vation of lung endothelium prior to the detection of tumor cells in
the lung. These findings support a model whereby calcineurin-
NFAT activation in the vasculature of early metastatic lesions
may play an important role promoting tumor cell seeding and
expansion at the metastatic site.
In tumor-bearing Dscr1/mice, calcineurin is hyperactivated
and leads to upregulation of the calcineurin-NFAT-dependent
target Ang2 in lung endothelium. In the presence of VEGF,
ANG2 promotes angiogenesis by displacing ANG1 binding to
the shared Angiopoietin receptor, TIE2, disrupting vessel quies-
cence (Saharinen and Alitalo, 2011). Although inflammatory
mediators and angiogenic factors have been shown to activate
ANG2 release, the molecular mechanisms regulating ANG2
expression have not yet been described. Here, we show that
the calcineurin-NFAT pathway directly transactivates Ang2 in
endothelial cells in the metastatic niche. Indeed, our data show
specific upregulation of ANG2 in early metastatic lesions in the
lung, prior to the arrival of tumor cells that preferentially metasta-
size to the lung. With recent studies demonstrating an important
role for calcineurin-NFAT in the innate immune system (Fric et al.,
2012), it is likely that increased calcineurin-NFAT signaling in
innate immune cells contribute to metastatic progression. For
example, NFAT has been shown to regulate inflammatory gene
expression in macrophages (Elloumi, et al., 2012), and with
polarized macrophages known to promote metastasis, upregu-
lated calcineurin-NFAT activation in these cells could play a
role in the increased metastases observed in Dscr1/ mice.
However, the output of increased calcineurin signaling in macro-
phages from Dscr1/mice in the context of macrophage polar-
ization and metastases has not yet been investigated.
While calcineurin-NFAT signaling is activated by increased
intracellular calcium levels, it is clear that calcineurin function is
not regulated in a straightforward binary manner. Variable levels
of calcineurin activation lead to differential expression of NFAT-
dependent target genes as evidenced in a number of systems.
For example, in lymphocytes, primary activation of T cells
leads to calcineurin-NFAT-dependent production of cytokines
such as interleukin (IL)-2, IL-4, and interferon gamma, critical
tomount an immune response.However, secondary activation of
T cells transactivates Fas ligand initiating lymphocyte apoptosis.or bearing Dscr1/ mice. Xenografted tumors ranged from (1) 500 mm3 to
. *p < 0.01 compared to ANG2 levels in the lungs.
metastatic lung lesions (upper) or primary lung adenocarcinoma (lower) were
ells. The scale bar represents 50 mm. Quantification of ANG2 expression in the
g tissue is shown on the right. Data are represented as mean ± SEM of each
y lung adenocarcinoma.
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Figure 5. Increased VEGF Levels in the Lungs of Tumor-Bearing Mice
(A) VEGF levels were quantified by ELISA in the plasma, lung, kidney, or liver lysates fromDscr1/mice with andwithout LLC tumors. *p < 0.01 compared to each
control; n = 10. NS, nonsignificant.
(B) VEGF levels were quantified in lungs and flank tumor extracts harvested from LLC tumor-bearing Dscr1/ mice. Xenografted tumors ranged from
(1) 500 mm3 to (2) 1,200 mm3 to (3) 1,500 mm3. Data are represented as mean ± SEM. *p < 0.01 compared to VEGF levels in the lungs; n = 3.
(C) Representative images of sections from LLC flank tumors (200 mm3) or lungs harvested from WT or Dscr1/ mice and immunostained with antibodies
against phospho-VEGFR2 (red) and PECAM1 (green). Arrows indicate costaining of phospho-VEGFR2 and PECAM1. Percentage of activated endothelium in
(legend continued on next page)
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Thus, the output of calcineurin-NFAT signaling in lymphocytes is
influenced by the nature of T cell activation (Ryeom et al., 2003).
Similarly, we have shown in this work and previously published
studies that during tumor growth, high levels of VEGF in the pri-
mary tumor microenvironment lead to upregulation of Fas ligand
in endothelial cells and subsequent endothelial cell apoptosis
(Ryeom et al., 2008). Conversely, more moderate levels of
VEGF in the lung activate ANG2 expression in the lung endothe-
lium, thus triggering endothelial cell activation in the lung prior to
the detection of tumor cells. Further studies are needed to deter-
mine the mechanism by which VEGF levels are regulated in
different organ environments during tumor growth, although it
is likely that immune cell infiltration is a source of VEGF in the
lungs. How varying doses of VEGF can differentially regulate
calcineurin-NFAT targets also remains to be investigated, as
does determining whether increasing VEGF levels control the
amplitude or the duration of calcineurin signaling. It is possible
that activation of specific calcineurin-NFAT targets could involve
unique NFAT binding partners, downregulation of inhibitors, or
different degrees of occupancy by NFAT complexes on target
genes.
To determine whether the calcineurin-NFAT-ANG2 signaling
axis was necessary for the establishment or progression of
lung metastases, we inhibited this pathway both genetically
with transgenic endothelial cell overexpression of the endoge-
nous calcineurin inhibitor DSCR1 and by adenoviral delivery of
the extracellular domain of the ANG2 receptor, soluble TIE2
(sTIE2). In both of these scenarios, lung metastases were signif-
icantly inhibited using two different transplanted tumor models
that metastasize to the lung. Thus, these data implicate the
requirement for calcineurin-NFAT-ANG2 signaling in the vascu-
lature of the target organ to promote tumor metastases. Impor-
tantly, the clinical relevance of these observations is supported
by our examination of both primary colon tumors and lung
metastases resected from patients. Immunohistochemical
studies of six patients demonstrate increased ANG2 expression
specifically in the endothelium of lung metastases, but not in the
vasculature of primary colon tumors, lending further confirma-
tion of our model whereby ANG2 expression in the lung endothe-
lium promotes metastasis to this organ.
With several antiangiogenic therapies targeting ANG2
currently being developed, understanding the mechanisms un-
derlying ANG2 regulation in the metastatic niche are important
and timely (Gerald et al., 2013). Collectively, our data implicate
moderate levels of VEGF in the lungs as a key factor in regulating
the calcineurin-NFAT-ANG2 pathway in lung endothelium prior
to the arrival of tumor cells. Our studies indicate that activation
of this pathway is necessary for lung metastases and suggest
that activation of the calcineurin pathway could represent a gen-primary tumors and lungswas quantified as the ratio of phospho-VEGFR2 to PECA
to WT; n = 4.
(D) Western blot of phospho-VEGFR2 and total VEGFR2 expression in lung, live
(500 mg/kg, i.v.) or control saline. The data are representative of three independ
(E) VEGF levels were quantified by ELISA in the plasma, lung, kidney, or liver tissue
each control; n = 10.
(F) qPCR of Ang2 and FasL mRNA in primary lung endothelial cells after VEGF tr
mean ± SD relative to b-actin mRNA; n = 3. *p < 0.05 compared to untreated.eral response of the tumor microenvironment to support the
expansion of micrometastases in target organs.
EXPERIMENTAL PROCEDURES
Tumor Models and Treatment Studies
WT C57BL/6j and Balb/c mice were purchased from Clea Japan. Dscr1/
mice on C57BL/6j and Balb/c backgrounds have been previously described
(Ryeom et al., 2003). All animal care and experimental protocols were per-
formed with the approval of the International Animal Care and Use Committee
of the University of Tokyo.
For lung colonization, B16-F10 (5 3 105 cells in 100 ml PBS) cells were
injected i.v. into 6-week-old WT or Dscr1/ mice. For our tumor models, a
suspension of LLC cells (2 3 106 cells per 100 ml PBS) was subcutaneously
implanted into the flank region of 6-week-old WT or Dscr1/ mice. For our
orthotopic renal cell carcinoma implantation model, a suspension of Renca
cells (53 105 cells per 50 ml Matrigel) was injected into the subcapsular space
of the left kidney of WT or Dscr1/ mice.
For CsA treatment, mice were injected with 1 mg/kg CsA or vehicle (olive oil)
intraperitoneally (i.p.) every other day. For the endotoxemia model, mice were
injected i.p. with normal saline (control) or LPS (16mg/kg) from E. coli serotype
0111:B4 (Sigma-Aldrich). To administer adenovirus, 5 R 109 plaque-forming
units of either Ad-sTIE2-Fc or Ad-control-Fc were injected i.v.
Generation of TIE2-DSCR1-1-IRES-LacZ Transgenic Mice
The mouse Tie2 promoter expression cassette containing 1,760 bp 50-flanking
region, exon 1 (318bp), and the core intronic enhancer (300 bp) was used for
endothelial cell expression (Minami et al., 2003). The human DSCR1 short iso-
form cDNA and bacterial b-galactosidase gene were subcloned into pIRES2
(Clontech) and then inserted into a Tie2 expression cassette. The transgene
was linearized by SalI and injected into mouse embryos by the transgenic
facility (Tsukuba University, Japan). Mice were genotyped by Southern blot-
ting. Three independent transgenic lines were generated and crossed onto a
C57BL/6j background.
Cell Culture
Human lung primary endothelial cells were purchased and cultured in EGM-2
MV complete medium (Lonza). Isolation and culture of primary mouse endo-
thelial cells from lung and liver were done using Miltenyi magnetic beads con-
jugated to anti-FITC monoclonal antibody selecting for endothelial cells after
incubation with CD31-FITC and then reselected after incubation with FITC-
Lectin as previously described in detail (Ryeom et al., 2008). B16-F10 cells
(ATCC CRL-6475) and LLC (ATCC CRL-1642) were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS). Renca cells (ATCC CCL-2947) were grown in RPMI
1640 medium plus 10% FBS. 3LLC (Hiratsuka et al., 2008) were grown and
passaged in Balb/c nude mice.
Soluble TIE2 Adenovirus Construction
Amino acids 1–743 corresponding to exons 1–8, of mouse TIE2 (NCBI:
BC050824) was amplified by PCR from mouse lung RNA and ligated to the
human immunoglobulin Fc fragment. This mTIE2-Fc DNA fragment was subcl-
oned into pENTR4 (Invitrogen) and cloned into an adenoviral vector with
recombinase (Invitrogen). pAd-sTIE2-Fc was transfected into HEK293 cells
for adenoviral packaging. Adenovirus titer was quantified with Adeno-X rapid
titer kit (Clontech) following the manufacturer’s instructions.M1positive signals. Data are represented asmean ±SD. p < 0.0001 compared
r, and kidney tissue harvested 10 min after treatment of WT mice with VEGF
ent experiments.
lysates fromWTmice with andwithout B16-F10 tumors. *p < 0.01 compared to
eatment at the indicated concentrations for 8 hr. Data are represented as the
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Figure 6. Endothelial-Specific Expression of DSCR1 Blocks Tumor Growth and Tumor Metastases to the Lung
(A) Representative immunofluorescence images of lacZ (green) and PECAM1 (red) staining of primary tumors and lungs harvested from Tie2-h DSCR1-lacZ
transgenic (Tg) mice; n = 8.
(B) Real-time qPCR expression of h DSCR1 mRNA in B16-F10 xenograft tumors from WT and DSCR1 Tg mice. Results are represented as the mean ± SEM
expression levels relative to b-actin mRNA, performed in triplicate; n = 3. *p < 0.01 compared to WT controls.
(C) Luciferase activity driven by NFAT response elements in lung endothelial cells fromWT andDSCR1 Tgmice. Results are shown as themean ± SD of luciferase
activity relative to WT performed in triplicate; n = 5. *p < 0.01 compared to luciferase activity in lung endothelial cells from WT mice.
(D) Tumor volume of B16-F10 cells was measured on the indicated days after s.c. inoculation into the flanks of WT or DSCR1 Tg mice (n = 8).
(E) Representative images of tumor xenografts 14 days after B16-F10 inoculation from WT and DSCR1 Tg mice; n = 8.
(F) Vascular density was quantified by PECAM1 immunostaining of sections of B16-F10 tumors harvested fromWT and DSCR1 Tg mice. Data are expressed as
mean ± SD; n = 8. *p < 0.05 compared to WT.
(G) Representative images of lungs harvested from WT and DSCR1 Tg mice 20 days after inoculation with B16-F10 cells (i.v.). H&E staining of lung sections is
shown on the right. The scale bar represents 50 mm. n = 10.
(H) B16-F10 melanoma metastasis invasion rate was quantified by the percentage of metastatic tumor area relative to total lung area. *p < 0.001 compared
to WT; n = 10.
See also Table S3.
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Figure 7. Adenoviral Delivery of Soluble TIE2 Decreases ANG2 Expression and Inhibits Lung Metastases
(A) Plasma sTIE2 levels were measured on the indicated days by ELISA after i.v. delivery of control (Ad-control) or adenoviral-sTIE2-Fc (Ad-sTIE2-Fc). Results are
represented as the mean ± SEM; n = 8. *p < 0.001 compared to controls at each day.
(B) ANG1 and ANG2 expression were quantified by ELISA in lungs harvested fromWT orDscr1/mice after i.v. delivery of Ad-control or Ad-sTIE2-Fc for 4 days.
Results are represented as the mean ± SEM (n = 6). *p < 0.01.
(legend continued on next page)
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ANG2 Promoter Constructs
The human ANG2 promoter was cloned from the BAC clone RP11-1065H2.
Promoter region (580 to +330) was amplified by PCR and subcloned into
pGL4.10 (Promega). Intron 1 and intron 2 of ANG2 was amplified by PCR
and subcloned into the pGL4.10. Consensus NFAT binding sites are indicated
in bold in Table S2, with point mutations (GGAA to GACT) generated using
the QuikChange XL site-directed mutagenesis kit (Stratagene). Promoter
sequences are shown in Table S2.
Immunohistochemistry
Mice were perfused with 2% paraformaldehyde in PBS. Tissues were har-
vested and fixed with 2% paraformaldehyde then immersed in 30% sucrose
for 20 hr at 4C. Cyrosectioned slides were treated with acetone for 10 min,
blocked with protein blocker (Dako), and incubated with first antibody for
20 hr at 4C. Slides were washed and incubated with an Alexa Fluor-labeled
secondary antibody (Invitrogen) for 1 hr, washed in PBS, mounted in ProLong
Gold anti-fade reagent with DAPI (Invitrogen), and examined by fluorescent
microscopy. Antibodies against PECAM1, VCAM1, E-selectin, ICAM2, and
TIE2 were obtained from BD PharMingen. Antibodies against LacZ and
ANG2 were from MBL and Abcam, respectively. Anti-ANG1 was from Milli-
pore. Anti-DSCR1 was described previously (Minami et al., 2006).
DNA Microarray
Endothelial cells or whole-lung RNAs were harvested and purified with TRIzol
(Invitrogen). Preparation of complementary RNA and hybridization of probe
arrays were performed according to the manufacturer’s instructions
(Affymetrix) with detailed protocols provided in the Extended Experimental
Procedures. Annotation of the probe numbers and targeted sequences are
shown on the Affymetrix web page.
ChIP-Seq Analysis
All protocols for Illumina/Solexa sequence preparation, sequencing, and qual-
ity control were according to Illumina with some modifications as previously
described (Kanki et al., 2011). Detailed protocols are provided in the Extended
Experimental Procedures.
VEGFR2 Activation
Murine recombinant VEGF (Peprotec) was administrated (i.v.) to WT C57BL/6j
mice. Tenminutes later, lung, liver, and kidney tissuewere harvested and lysed
with RIPA buffer (Cell Signaling). Protein concentrations from whole-tissue ex-
tracts were quantified and 12 mg of each tissue was immunoprecipitated with
anti-VEGFR2 (Flk-1) antibody (Cell Signaling). Immunoprecipitated samples
were separated by SDS-PAGE and probed with a phospho-specific VEGFR2
antibody (Cell Signaling). The membrane was stripped and reprobed with total
VEGFR2 antibody.
VEGF, ANG1, ANG2, and Soluble TIE2 Levels
Blood or tissue homogenates were collected from the indicated mice and
centrifuged. Plasma or tissue eluents were harvested and each sample was
diluted to 5- to 200-fold. VEGF and soluble TIE2 levels were measured using
Quantikine ELISA kits (R&D Systems). ANG1 and ANG2 level were measured
by an ELISA kit (UCSN Life Science).(C) Representative images of lungs and kidneys harvested from Dscr1/ mice
injections of Renca cells in the kidney. Organs were harvested 20 days after tumor
right with results represented as the mean ± SD. *p < 0.0001 compared to Ad-co
(D) Representative images of lungs harvested from Dscr1/ mice at the indicat
24 hr after tumor cell inoculation. The number of tumor colonies are shown on
Ad-control; n = 6.
(E) qPCR of Vcam-1 and E-selectin mRNA in lungs harvested from either WT
Ad-control or Ad-sTIE2-Fc. Results are represented as the mean ± SD express
compared to non-tumor-bearing mice.
(F) Representative images of lung sections harvested from Dscr1/ mice after i.v
Ad-sTIE2. Sections were immunostained with antibodies to VCAM-1 (red), ICAM
DAPI (blue) (lower row). The scale bar represents 50 mm.
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Data are presented as mean ± SD or SEM as indicated. p values were calcu-
lated using a two-tailed unpaired Student’s t test. The Wilcoxon log-rank test
was used for mouse survival studies. Statistical tests and graphing were done
with KaleidaGraph (Synergy Software). A p value less than 0.05 was consid-
ered significant.
For further details, please refer to the Extended Experimental Procedures
and Tables S3 and S4.
ACCESSION NUMBERS
The NCBI accession number for the data reported in this paper is GSE48841.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and four tables and can be found with this article online at http://dx.
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